Search / 617 results found

from
to
  • Updated

RADNOR, Pa., Dec. 5, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Snap Inc. ("Snap") (NYSE: SNAP). The action charges Snap with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's advertising business.  As a result of Snap's materially misleading statements made to the market, Snap investors have suffered significant losses.

  • Updated

RADNOR, Pa., Dec. 5, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Novavax, Inc. ("Novavax") (NASDAQ: NVAX). The action charges Novavax with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Novavax's materially misleading statements, Novavax investors have suffered significant losses.

  • Updated

BENSALEM, Pa., Dec. 3, 2021 /PRNewswire/ -- Law Offices of Howard G. Smith continues its investigation on behalf of Talis Biomedical Corporation ("Talis" or the "Company") (NASDAQ: TLIS) investors concerning the Company's possible violations of the federal securities laws.

  • Updated

RADNOR, Pa., Dec. 3, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against D-MARKET Elektronik Hizmetler ve Ticaret Anonim Şirketi a/k/a D-MARKET Electronic Services & Trading d/b/a Hepsiburada ("Hepsiburada") (NASDAQ: HEPS). The action charges the company with violations of the federal securities laws, including omissions and fraudulent misrepresentations involving its American Depositary Receipts ("ADRs") pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Hepsiburada's July 2021 initial public offering ("IPO"). Hepsiburada's materially misleading statements regarding their business, operations, and prospects caused investors to suffer significant losses.